Difference between revisions of "Vinorelbine (Navelbine)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Drug index" to "Category:Drugs")
m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA")
Line 45: Line 45:
 
[[Category:Small cell lung cancer medications]]
 
[[Category:Small cell lung cancer medications]]
  
−
[[Category:Drugs FDA approved in 1994]]
+
[[Category:FDA approved in 1994]]
 
[[Category:WHO Essential Cancer Medicine]]
 
[[Category:WHO Essential Cancer Medicine]]

Revision as of 19:08, 30 July 2018

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Disease for which it is used

Patient drug information

History of changes in FDA indication

  • 12/23/1994: Initial FDA approval

References

  1. ↑ 1.0 1.1 Vinorelbine (Navelbine) package insert
  2. ↑ Vinorelbine (Navelbine) package insert (locally hosted backup)
  3. ↑ Vinorelbine (Navelbine) patient drug information (Chemocare)
  4. ↑ Vinorelbine (Navelbine) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Vinorelbine_(Navelbine)&oldid=29247"